Clinical Trials Logo

Healthy Individuals clinical trials

View clinical trials related to Healthy Individuals.

Filter by:

NCT ID: NCT01134978 Completed - Healthy Individuals Clinical Trials

Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study

GRID12007
Start date: November 2007
Phase: Phase 1
Study type: Interventional

The overall goal of this study is to gain insight into the neural mechanisms of learning multiple tasks. By examination of cognitive and behavioral output during the performance and learning of several computer maze tasks, and through a detailed examination of the neural activity obtained from functional near-infrared (fNIR) and electroencephalography (EEG), it may be possible to gain insight into the impact of the amount of practice and the organization of practice has on learning fine motor skills. This insight may provide direction as to how to better develop instructional and rehabilitation protocols in addition to clinical interventions to facilitate recovery of function, relearning and transfer of cognitive and fine motor skills based upon neural responses to physical practice.

NCT ID: NCT01113944 Completed - Healthy Individuals Clinical Trials

Training in the Workplace

Start date: April 2010
Phase: N/A
Study type: Interventional

We are testing whether various cognitive training procedures can enhance cognition and brain function

NCT ID: NCT00980408 Completed - Healthy Individuals Clinical Trials

The Influence of Glutamate on Memory in Humans

Start date: June 2008
Phase: N/A
Study type: Interventional

The hippocampus is particularly laden with n-methyl-d-aspartate (NMDA) receptors, and is at the same time one of the most important sites in declarative memory. The rationale of this study is that the NMDA partial agonist D-Cycloserine will promote learning compared to a placebo. On the other hand, the NMDA receptor antagonist Memantine might lead to reduced memory. We believe that the influence of NMDA receptors on memory can be determined via acute co-activation of the NMDA receptors with Cycloserine® (King Pharmaceuticals Ltd, active ingredient: DCycloserin, dose: 250 mg) and Memantine (Axura®, Merz, active ingredient: Memantine, dose: 20 mg)on both a behavioral and functional (fMRI) level.